1. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757?766
2. Boyd MR, Paull KD, Rubinstein LR (1992) In cytotoxic anticancer drugs: Models and concepts for drug discovery and development. In: Datadisplay and analysis strategies for the NCI disease orientedin vitro antitumor drug screen, edited by Valeriote FA, Corbett TH, Baker LH, Kluwer Academic Publishers, Boston, pp 11?34
3. Paull KD, Hamel E, Malspeis L (1993) Prediction of biochemical mechanisms of action from the in vitro antitumor screen of the National Cancer Institute. In: Cancer Chemotherapeutic Agents, edited by Foye WE, American Chemical Society, Washington, D. C.
4. Paull KD, Lin CM, Malspeis L, Hamel E (1992) Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 52: 3892?3900
5. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088?1092